Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Propanc Biopharma Inc PPCB

Healthcare Biotechnology
Propanc Biopharma, Inc. is an Australia-based clinical biopharmaceutical company. The Company is focused on the development of novel cancer treatments for patients suffering from pancreatic, ovarian and colorectal cancers. The Company has developed a rational, composite formulation of anti-cancer compounds, which together exert a number of effects designed to control or prevent tumors from... see more

Recent & Breaking News (OTCPK:PPCB)

The Road To The Cure: 4 Biotech Stocks Advancing New Therapies In The Fight Against Cancer

Accesswire May 17, 2015

Propanc Engages Maxim Group LLC as Strategic Advisors

Accesswire May 13, 2015

Propanc to Study Effects of PRP on Cancer Stem Cells

Accesswire May 12, 2015

PROPANC SETTLES OUTSTANDING CONVERTIBLE DEBTS

Accesswire May 7, 2015

PRP Demonstrates Safety and Tolerability in Mice

Accesswire May 5, 2015

Propanc to Settle Outstanding Convertible Debts

Accesswire April 16, 2015

Propanc to Feature in NY Times Sunday Edition Magazine

Accesswire April 8, 2015

Propanc to Present at SeeThruEquity 4th Annual Investor Conference

Accesswire April 7, 2015

Propanc Announces Joint Research Partnership

Accesswire March 19, 2015

Propanc Raises Capital to Complete Next Round of Animal Studies

PR Newswire March 17, 2015

Small Biotec Firm Quietly Makes +1,000% Price Move

Accesswire March 17, 2015

Propanc Helping to Unravel Mystery Associated with Carcinomas

PR Newswire March 11, 2015

Biotech Company Could Be on the Cusp of New Proenzyme Drug for the Treatment and Prevention of Certain Forms of Cancer

Accesswire March 9, 2015

Oncology Biotech Company Could Be on the Cusp of New PRP Drug for the Treatment and Prevention of Metastatic Cancer

Accesswire March 9, 2015

Propanc Initiates Next Phase of R&D Activities

PR Newswire February 23, 2015

Propanc Announces Latest Company Initiatives

PR Newswire January 13, 2015

Propanc enters into $5 million Equity Purchase Agreement with Southridge Partners

PR Newswire September 22, 2014

Propanc Stock Now DWAC/FAST Eligible

GlobeNewswire July 18, 2014

Propanc Secures $400,000 Bridge Financing Through Private Placement

GlobeNewswire June 6, 2014

Propanc Makes Substantial Progress With Lead Patent Application for New Cancer Treatment in Key Global Regions

GlobeNewswire May 23, 2014